Tenaya Therapeutics (TNYA)
US Market

Tenaya Therapeutics (TNYA) Income Statement


Tenaya Therapeutics Income Statement

Last quarter (Q4 2023), Tenaya Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Tenaya Therapeutics's net income was $-29.95M. See Tenaya Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 131.19M$ 131.19M$ 125.62M$ 72.81M$ 38.91M$ 27.71M
Operating Income
$ -131.19M$ -131.19M$ -125.62M$ -72.81M$ -38.91M$ -27.71M
Net Non Operating Interest Income Expense
$ 7.06M$ 7.06M$ 1.95M$ 108.00K$ 87.00K$ 453.00K
Other Income Expense
$ -53.00K$ -53.00K$ -2.00K$ 23.00K$ 430.00K$ 1.03M
Pretax Income
$ -124.08M$ -124.08M$ -123.67M$ -72.72M$ -38.40M$ -26.23M
Tax Provision
----$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -124.10M$ -124.10M$ -123.67M$ -72.72M$ -38.40M$ -26.23M
Basic EPS
$ -1.67$ -1.68$ -2.76$ -4.10$ -1.42$ -0.97
Diluted EPS
$ -1.67$ -1.68$ -2.76$ -4.10$ -1.42$ -0.97
Basic Average Shares
$ 295.14M$ 73.79M$ 44.82M$ 17.73M$ 27.07M$ 27.07M
Diluted Average Shares
$ 295.14M$ 73.79M$ 44.82M$ 17.73M$ 27.07M$ 27.07M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 131.19M$ 131.19M$ 125.62M$ 72.81M$ 38.91M$ 27.71M
Net Income From Continuing And Discontinued Operation
$ -124.10M$ -124.10M$ -123.70M$ -72.72M$ -38.40M$ -26.23M
Normalized Income
$ -46.67M$ -98.03M$ -97.70M-$ -38.40M$ -26.23M
Interest Expense
$ -126.06M$ -124.08M$ -123.67M$ -72.83M$ -38.91M$ -27.71M
$ -91.86M$ -111.95M$ -115.26M$ -75.83M$ -36.43M$ -25.72M
Currency in USD

Tenaya Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis